A FAT jab user has revealed that after stopping the injections for eight weeks, she has now realised she is a “Mounjaro lifer ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Once users stop taking Mounjaro, their appetite is no longer suppressed, and there's a decent chance that they will revert ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

One person using Mounjaro revealed they had a peculiar ‘magic mushroom’ sensation when starting the medication in a discussion about side effects on Reddit ...

A MOUNJARO user has candidly opened up on what happened after she used fat jabs for just four weeks. Despite being “really happy” with losing two to three lbs a week on the injections, Megan ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...